Second Sight Medical Products (NASDAQ:EYES) Now Covered by Analysts at StockNews.com
Second Sight Medical Products (NASDAQ:EYES) Now Covered by Analysts at StockNews.com
Investment analysts at StockNews.com initiated coverage on shares of Second Sight Medical Products (NASDAQ:EYES – Get Rating) in a research report issued to clients and investors on Sunday. The firm set a "sell" rating on the medical device company's stock.
在週日發佈給客户和投資者的一份研究報告中，斯托克新聞網的投資分析師發起了對第二視力醫療產品(納斯達克：Eyes-Get Rating)股票的報道。該公司對這家醫療器械公司的股票設定了“賣出”評級。
Second Sight Medical Products Price Performance
慧眼醫療產品價格表現
Second Sight Medical Products has a 52-week low of $3.42 and a 52-week high of $12.72. The stock has a fifty day simple moving average of $5.80 and a 200-day simple moving average of $5.21.
第二視力醫療產品的52周低點為3.42美元，52周高位為12.72美元。該股的50日簡單移動均線為5.80美元，200日簡單移動均線為5.21美元。
Hedge Funds Weigh In On Second Sight Medical Products
對衝基金看好第二視覺醫療產品
A number of hedge funds have recently bought and sold shares of the business. Jane Street Group LLC raised its position in Second Sight Medical Products by 111.8% in the 2nd quarter. Jane Street Group LLC now owns 21,601 shares of the medical device company's stock worth $44,000 after buying an additional 11,403 shares during the last quarter. Vanguard Group Inc. raised its position in Second Sight Medical Products by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 1,221,704 shares of the medical device company's stock worth $1,747,000 after buying an additional 17,164 shares during the last quarter. Virtu Financial LLC raised its position in Second Sight Medical Products by 130.6% in the 2nd quarter. Virtu Financial LLC now owns 31,258 shares of the medical device company's stock worth $63,000 after buying an additional 17,703 shares during the last quarter. Millennium Management LLC purchased a new position in Second Sight Medical Products in the 2nd quarter worth about $207,000. Finally, Renaissance Technologies LLC purchased a new position in Second Sight Medical Products in the 1st quarter worth about $249,000.
一些對衝基金最近買賣了該公司的股票。簡街集團在第二季度將其在第二視覺醫療產品公司的頭寸提高了111.8%。簡街集團現在擁有21,601股這家醫療設備公司的股票，價值44,000美元，在上個季度又購買了11,403股。先鋒集團(Vanguard Group Inc.)在第一季度將其在第二視力醫療產品的頭寸提高了1.4%。先鋒集團現在持有這家醫療設備公司1,221,704股股票，價值1,747,000美元，上個季度又購買了17,164股。維圖金融有限責任公司在第二季度將其在第二視覺醫療產品的頭寸提高了130.6%。Virtu Financial LLC現在持有這家醫療設備公司31,258股股票，價值63,000美元，上個季度又購買了17,703股。千禧管理有限責任公司在第二季度購買了一個新的第二視覺醫療產品頭寸，價值約207,000美元。最後，復興科技有限責任公司在第一季度收購了第二視力醫療產品公司的一個新頭寸，價值約24.9萬美元。
About Second Sight Medical Products
關於第二視覺醫療產品
Second Sight Medical Products, Inc develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury.
第二視力醫療產品公司開發、製造和銷售植入式視覺假體，旨在為盲人提供人工視覺。它開發了治療視障人羣的技術。該公司提供獵户座視覺皮質假體系統，這是一種植入式皮質刺激設備，旨在為因各種原因而失明的個人提供有用的人工視覺，包括青光眼、糖尿病視網膜病變、視神經損傷或疾病以及眼睛損傷。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on Second Sight Medical Products (EYES)
- Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
- MarketBeat: Week in Review 9/19 – 9/23
- Why Does Tesla Stock Remain Resilient?
- 2 Semiconductor Stocks To Watch For Reversals
- Is Costco's Post-Earnings Price Weakness A Good Time To Buy?
- 免費獲取StockNews.com關於第二視力醫療產品的研究報告(Eyes)
- 華爾街對Datadog的熱情會帶來巨大的收益嗎？
- MarketBeat：回顧一週9/19-9/23
- 為什麼特斯拉的股票保持彈性？
- 需要關注的2只半導體類股走勢逆轉
- 好市多盈利後價格疲軟是買入的好時機嗎？
Receive News & Ratings for Second Sight Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.
接受新聞和評級的第二視覺醫療產品日報-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊，接收對Second Sight醫療產品和相關公司的最新新聞和分析師評級的每日摘要。
譯文內容由第三人軟體翻譯。